A new option for stubborn high blood pressure
Hypertension is a pervasive and often silent condition that drives significant cardiovascular risk. In France alone, an estimated 17 million people live with high blood pressure, and more than 6 million remain undiagnosed. Even with lifestyle changes and medication, many patients still fail to reach safe targets. For roughly 30% of people, standard therapies leave blood pressure uncontrolled, underscoring the need for new and durable solutions.
Twice-yearly dosing shows stronger control
An international phase 2 trial, known as Kardia-2, explored a novel approach for patients with poorly controlled hypertension. The study enrolled 663 adults across eight countries, all of whom remained hypertensive despite guideline-recommended treatments. Participants received standard drugs such as amlodipine, indapamide, or olmesartan, with some randomized to add a new twice-yearly injection. Those given the investigational agent achieved a larger and steadier drop in systolic blood pressure, outperforming usual care alone.
A simple **zilebesiran** injection every six months could help stabilize blood pressure in patients resistant to standard treatments. © Alemon77, Adobe Stock
How the therapy works
The investigational medicine, zilebesiran, uses RNA interference to selectively silence a key blood-pressure pathway. It targets angiotensinogen, a liver-produced precursor driving the renin–angiotensin–aldosterone system. By reducing angiotensinogen production at the source, the drug promotes sustained blood vessel dilation and lowers pressure over many months. Early results suggest consistent efficacy, but larger trials must clarify long-term safety and rare adverse events.
Why simplicity matters
Adherence is a chronic challenge in hypertension, with nearly half of patients discontinuing therapy within a year. A twice-yearly injection could dramatically simplify care and help patients maintain control. As principal investigator Dr. Manish Saxena noted, “The simplicity of a twice-yearly injection could help millions of patients better manage their condition.” Fewer daily pills may reduce friction and minimize the peaks and troughs that come with inconsistent dosing.
Key points at a glance
- The therapy is given as a twice-yearly injection, aiming for sustained blood-pressure control.
- It uses RNA interference to reduce angiotensinogen, tackling hypertension at its source.
- In the Kardia-2 trial, systolic pressure fell more and stayed more stable versus standard care alone.
- It is designed as an add-on to existing medications, not a wholesale replacement.
- Larger phase 3 trials must confirm safety and hard outcomes like heart attack and stroke.
Who could benefit most
Patients with persistently high readings despite multiple drugs may see the greatest benefit. Those who struggle with complex regimens could also gain from a simplified, twice-yearly schedule. The approach may help clinicians close adherence gaps while keeping proven therapies in place. Real-world uptake will depend on access, cost, and integration into clinical guidelines.
Balancing promise with prudence
While the phase 2 findings are encouraging, they are not the final word. Phase 3 trials must test whether lowering blood pressure translates into fewer events, including heart attacks and strokes. Researchers will also assess durability across diverse populations, potential drug–drug interactions, and long-term hepatic or renal effects. Robust evidence will determine whether the therapy shifts routine practice or stays reserved for select cases.
What comes next
If confirmed in large-scale studies, a twice-yearly injection could reshape hypertension management for patients with difficult-to-control pressures. It would complement, not replace, foundational steps like diet, exercise, and sodium reduction. For now, clinicians can watch the emerging evidence while optimizing today’s proven therapies. The horizon looks notably brighter, but careful validation remains essential.
When will this be available in the USA, and what are the side effects